World Health Organization (WHO) and its relevant partners have revealed their plans to purchase 2 billion doses of vaccines for the most vulnerable people in the world
In its latest effort to curtail the spread of the coronavirus, the World Health Organisation and its key Partners has committed to the delivery of vaccines valued at approximately $18.1 billion
The plan revealed to the public yesterday and according to the official statement, the purchase and delivery of the 2 billion vaccines will cut across all countries across the globe with a major focus on the most vulnerable people around the world.
Going by the plan, it is predicted that the delivery of vaccines to all affected nations will be completed towards the end of 2021, and as such the WHO will prioritize the distribution of vaccines based on high-risk persons, including those above the age of 65.
While WHO and its Key partners including GAVI, the Vaccine Alliance, and Coalition for Epidemic Preparedness Innovation (CEPI) are yer to secure all funding to execute the project, it is estimated that approximately $18.1billion will be required to execute the proposed plan.
According to WHO, executing this project is in accordance with its goal of ensuring that all nations have access to therapeutic, diagnostics, and COVID-19 vaccines. That been said, countries that can afford to get the vaccine directly are allowed to use the direct purchase agreements which also secure them first inline position for receiving the vaccines.
Although this could be very detrimental for developing countries who may be more vulnerable and cannot afford the cost of purchasing the said cure, countries who are interested in the early purchase must be willing to pay ahead for the cost of making the vaccine making them the first in line to get the vaccine.
“It’s risky for them to do that and it’s also not ethically the right approach, because it leaves the rest of the world without vaccine doses,” said Soumya Swaminathan, WHO’s chief scientist.
According to Gavi GEO, Seth Berkley, about 7% of vaccines make it through preclinical development, and maybe 15% to 20% that enter the clinic is successful.